The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

Updated findings from the safety lead-in phase of the BEACON CRC trial showed an estimated survival time beyond historic controls from treatment with a triplet combination of encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer. 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.